OUR MISSION

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership.

OUR COMMITMENT TO GLOBAL SOCIAL RESPONSIBILITY (GSR)

We appreciate that the decisions we make and the actions we take can have a lasting impact on the world around us. That’s why operating as a responsible member of the communities in which we live, work and serve patients has always been a priority for us. Throughout our history, Mylan’s foundation and core business model have been focused on providing access to medicine and creating better health for a better world. From providing high quality medicine in more than 165 countries to finding ways to reduce our environmental impact, we are committed to helping lead positive change through social responsibility.

In 2018, we made several strides in formalizing our approach to GSR oversight:

• Established our global sustainability function as a direct report to our CEO
• Included GSR as a focus area for Mylan’s Executive Governance Team and global Risk Management Team
• Added GSR oversight as a formal component of the charter of the Risk Oversight Committee of Mylan’s Board of Directors
• Undertook our first formal process to identify the current topics of greatest GSR significance to our business and to our stakeholders

OUR VISION FOR GLOBAL SOCIAL RESPONSIBILITY

Global social responsibility is intrinsically woven within Mylan’s commitment to achieve our mission and deliver better health for a better world. It is what drives our enduring passion to improve access and serve unmet needs across all geographies, while respecting the environment and positively impacting our stakeholders.

OUR TEAM HELPING TO DELIVER BETTER HEALTH FOR A BETTER WORLD

Our passionate and talented global workforce of approximately 35,000 is fundamental in bringing our mission to life. Around the globe, our people understand how they as individuals are critical to expanding access to high quality medicine.

Employee Survey Highlights

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>81%</td>
<td>see a clear link between their work and the company’s mission</td>
</tr>
<tr>
<td>86%</td>
<td>think Mylan sets clear performance standards for quality</td>
</tr>
<tr>
<td>90%</td>
<td>agree that Mylan supports ethical behavior and practices</td>
</tr>
<tr>
<td>75%</td>
<td>say they are extremely satisfied with Mylan as a place to work</td>
</tr>
</tbody>
</table>

~35,000
GLOBAL WORKFORCE

©2019 Mylan N.V. All Rights Reserved.
The Mylan Better Health for a Better World logo is a registered trademark of Mylan Inc.
We know that what we do directly impacts the health and well-being of the patients we serve. As a result, protecting patient health and safety by ensuring the quality of our products is our highest priority and at the heart of how we operate across our network. In addition to producing high quality medicine, we continue to innovate to meet patient needs and relentlessly advocate for policies that put patients first.

In 2018:
- we supplied more than 7,500 products with the ability to treat 9 out of the top 10 global causes of death\(^1,2\)
- and reached more than 165 countries and territories, including 90% of low- and lower-middle-income countries,\(^3\)
- at an average selling price of 19¢ per dose.

Regulatory approvals for biosimilars in >65 countries

First to provide a trastuzumab biosimilar in Guatemala, Thailand and Pakistan.

Collaborated with >50 organizations worldwide on issues of global public health

Donated hundreds of millions of doses of medicines to organizations such as Americares, Brother’s Brother, Direct Relief International, Dispensary of Hope, Health Partners International of Canada and Heart to Heart International, among others, to assist those in need.

~40% of the nearly 22M\(^4\) HIV+ patients & ~60% of the world’s HIV+ children on treatment depend on one of our products.

In 2018, Mylan manufactured ~5 billion ARV tablets & capsules

12 R&D Centers with ~3,700 products\(^5\) pending approval or in development

40+ Manufacturing Facilities

~30% increase in renewable energy purchased

Provided hepatitis B and C treatments for >350,000 patients in low- and middle-income countries and supported free hepatitis screenings in countries such as Egypt and India.

Visit Mylan.com to read our complete 2018 progress report and learn more about global social responsibility at Mylan.

\(^1\)The remaining cause of death is road injury.
\(^3\)Income groups from the World Bank list of economies (Published June 2018)
\(^4\)http://www.unaids.org
\(^5\)Products taken from internal data and rounded

\(\text{Information presented is as of April 2, 2019.}\)